{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:43:39Z","timestamp":1788975819880,"version":"build-2803163510"},"reference-count":304,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T00:00:00Z","timestamp":1543190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Biochemistry and Biophysics"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.abb.2018.11.021","type":"journal-article","created":{"date-parts":[[2018,11,24]],"date-time":"2018-11-24T11:00:53Z","timestamp":1543057253000},"page":"15-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Natural and synthetic peptides in the cardiovascular diseases: An update on diagnostic and therapeutic potentials"],"prefix":"10.1016","volume":"662","author":[{"given":"Paolo","family":"Grieco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Gomez-Monterrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abb.2018.11.021_bib1","unstructured":"World Health Organization. http:\/\/www.who.int\/cardiovascular_diseases\/en\/."},{"key":"10.1016\/j.abb.2018.11.021_bib2","first-page":"S32","article-title":"Global progress in prevention of cardiovascular disease Cardiovasc","volume":"7","author":"Mendis","year":"2017","journal-title":"Diagn. Ther."},{"key":"10.1016\/j.abb.2018.11.021_bib3","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.jacc.2015.07.018","article-title":"Long-term use of cardiovascular drugs: challenges for research and for patient care","volume":"66","author":"Rossello","year":"2015","journal-title":"JACC (J. Am. Coll. Cardiol.)"},{"key":"10.1016\/j.abb.2018.11.021_bib4","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.2174\/1381612821666150817104635","article-title":"Recent advancement in the treatment of cardiovascular diseases: conventional therapy to nanotechnology","volume":"21","author":"Behera","year":"2015","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.abb.2018.11.021_bib5","series-title":"Basic and Clinical Pharmacology","author":"Katzung","year":"2017"},{"key":"10.1016\/j.abb.2018.11.021_bib6","series-title":"Handbook of Biologically Active Peptides","author":"Kastin","year":"2013"},{"key":"10.1016\/j.abb.2018.11.021_bib7","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.peptides.2004.04.017","article-title":"Urotensin II in the cardiovascular system","volume":"25","author":"Richards","year":"2004","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.11.021_bib8","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1152\/ajpheart.2000.279.6.H3031","article-title":"Urocortin, a member of the corticotropin- releasing factor family, in normal and diseased heart","volume":"279","author":"Nishikimi","year":"2000","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.abb.2018.11.021_bib9","series-title":"Endocrinology of the Heart in Health and Disease","first-page":"41","article-title":"Adrenomodullin","author":"Nishikimi","year":"2017"},{"key":"10.1016\/j.abb.2018.11.021_bib10","series-title":"Handbook of Biologically Active Peptides","first-page":"1437","article-title":"Urotensin peptides","author":"Takahashi","year":"2013"},{"key":"10.1016\/j.abb.2018.11.021_bib11","series-title":"Handbook of Biologically Active Peptides","first-page":"1428","article-title":"Urocortins","author":"Richards","year":"2013"},{"key":"10.1016\/j.abb.2018.11.021_bib12","series-title":"Handbook of Biologically Active Peptides","first-page":"1361","article-title":"Adrenomedullin peptides","author":"Kato","year":"2013"},{"key":"10.1016\/j.abb.2018.11.021_bib13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discover. Today Off."},{"key":"10.1016\/j.abb.2018.11.021_bib14","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1055\/s-0031-1278379","article-title":"Latest drug developments in the field of cardiovascular disease","volume":"19","author":"Stern","year":"2010","journal-title":"Int. J. Angiol."},{"key":"10.1016\/j.abb.2018.11.021_bib15","first-page":"949","article-title":"The search for new cardiovascular biomarkers","volume":"45","author":"Thomas","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.abb.2018.11.021_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tcm.2016.07.005","article-title":"Biomarkers in cardiovascular disease","volume":"27","author":"Dhingra","year":"2017","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.abb.2018.11.021_bib17","first-page":"533","article-title":"Neurohormones from fish tails: the caudal neurosecretory system. I. \u201cUrophysiology\u201d and the caudal neurosecretory system of fishes","volume":"41","author":"Bern","year":"1985","journal-title":"Recent Prog. Horm. Res."},{"key":"10.1016\/j.abb.2018.11.021_bib18","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/0006-291X(92)91095-8","article-title":"Isolation and primary structure of urotensin II from the brain of a tetrapod, the frog Rana ridibunda","volume":"188","author":"Conlon","year":"1992","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.abb.2018.11.021_bib19","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0196-9781(96)00193-3","article-title":"A proenkephalin A-derived peptide analogous to bovine adrenal peptide E from frog brain: purification, synthesis, and behavioral effects","volume":"17","author":"Conlon","year":"1996","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.11.021_bib20","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1749-6632.1998.tb10847.x","article-title":"A second somatostatin gene is expressed in the brain of the frog Ranaridibunda","volume":"839","author":"Tostivint","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.abb.2018.11.021_bib21","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/45809","article-title":"Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14","volume":"401","author":"Ames","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.abb.2018.11.021_bib22","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.peptides.2004.01.028","article-title":"Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries","volume":"25","author":"Maguire","year":"2004","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.11.021_bib23","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1006\/bbrc.1999.1796","article-title":"Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14","volume":"266","author":"Liu","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.abb.2018.11.021_bib24","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1124\/pr.114.009480","article-title":"International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: from structure to function","volume":"67","author":"Vaudry","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.abb.2018.11.021_bib25","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.bbrc.2003.09.102","article-title":"Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain","volume":"310","author":"Sugo","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.abb.2018.11.021_bib26","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/S0140-6736(02)08831-1","article-title":"Congestive heart failure and expression of myocardial urotensin II","volume":"359","author":"Douglas","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.abb.2018.11.021_bib27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0167-0115(02)00158-1","article-title":"Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure","volume":"110","author":"Dschietzig","year":"2002","journal-title":"Regul. Pept."},{"key":"10.1016\/j.abb.2018.11.021_bib28","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1097\/00004872-200112000-00011","article-title":"Co-expression of urotensin II and its receptor [GPR14] in human cardiovascular and renal tissues","volume":"19","author":"Matsushita","year":"2001","journal-title":"J. Hypertens."},{"key":"10.1016\/j.abb.2018.11.021_bib29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0024-3205(01)01101-8","article-title":"Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition","volume":"69","author":"Gray","year":"2001","journal-title":"Life Sci."},{"key":"10.1016\/j.abb.2018.11.021_bib30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1050-1738(00)00069-4","article-title":"Human urotensin-II, the most potent mammalian vasoconstrictor identified to dat as a therapeutic target for the management of cardiovascular disease","volume":"10","author":"Douglas","year":"2000","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.abb.2018.11.021_bib31","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/sj.bjp.0705743","article-title":"Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines","volume":"142","author":"Douglas","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib32","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/sj.bjp.0703690","article-title":"Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey","volume":"131","author":"Douglas","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib33","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.peptides.2007.08.024","article-title":"Urotensin II and atherosclerosis","volume":"29","author":"Loirand","year":"2008","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.11.021_bib34","first-page":"R361","article-title":"Contraction of major artery segments of rat by fish neuropeptide urotensin II","volume":"252","author":"Itoh","year":"1987","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.abb.2018.11.021_bib35","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/sj.bjp.0704051","article-title":"Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats","volume":"132","author":"Gardiner","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib36","doi-asserted-by":"crossref","first-page":"H925","DOI":"10.1152\/ajpheart.2001.280.2.H925","article-title":"Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries","volume":"280","author":"Stirrat","year":"2001","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.abb.2018.11.021_bib37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00210-004-0876-y","article-title":"Cardiovascular actions of human urotensin II\u2014considerations for hypertension","volume":"369","author":"Russell","year":"2004","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib38","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1161\/hh1101.092034","article-title":"Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase","volume":"88","author":"Sauzeau","year":"2001","journal-title":"Circ. Res."},{"key":"10.1016\/j.abb.2018.11.021_bib39","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/sj.bjp.0703601","article-title":"Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1","volume":"131","author":"Maguire","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib40","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1046\/j.1472-8206.2001.00032.x","article-title":"Comparison of the contractile responses of human coronary bypass grafts and monkey arteries to human urotensin-II","volume":"15","author":"Paysant","year":"2001","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/sj.bjp.0704448","article-title":"Urotensin II evokes potent vasoconstriction in humans in vivo","volume":"135","author":"B\u00f6hm","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib42","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1159\/000136932","article-title":"Pharmacological effects of urotensins. I. Regional vascular effects of urotensins I and II in the rat","volume":"13","author":"Medakovic","year":"1975","journal-title":"Pharmacology"},{"key":"10.1016\/j.abb.2018.11.021_bib43","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00210-001-0503-0","article-title":"Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents","volume":"365","author":"Camarda","year":"2002","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib44","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.tem.2004.03.007","article-title":"Urotensin II: the old kid in town","volume":"15","author":"Onan","year":"2004","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.abb.2018.11.021_bib45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/sj.bjp.0703811","article-title":"Cardiostimulant effects of urotensin-II in human heart in vitro","volume":"132","author":"Russell","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib46","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11906-007-0010-x","article-title":"Therapeutic potential of blockade of the urotensin II system in systemic hypertension","volume":"9","author":"Krum","year":"2007","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.abb.2018.11.021_bib47","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/CRD.0b013e31815c8048","article-title":"Urotensin II: a new pharmacologic target in the treatment of cardiovascular disease","volume":"16","author":"Desai","year":"2008","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.abb.2018.11.021_bib48","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1097\/01.hjh.0000125452.28861.f1","article-title":"Plasma concentration of urotensin II is raised in hypertension","volume":"22","author":"Cheung","year":"2004","journal-title":"J. Hypertens."},{"key":"10.1016\/j.abb.2018.11.021_bib49","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijcard.2005.07.008","article-title":"Exercise urotensin II dynamics in myocardial infarction survivors with and without hypertension","volume":"110","author":"Rdzanek","year":"2006","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.abb.2018.11.021_bib50","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/sj.bjp.0703314","article-title":"Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat","volume":"130","author":"MacLean","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib51","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11906-006-0026-7","article-title":"Urotensin-II and cardiovascular diseases","volume":"8","author":"Bousette","year":"2006","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.abb.2018.11.021_bib52","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ijcard.2006.05.016","article-title":"Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans","volume":"117","author":"Khan","year":"2007","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.abb.2018.11.021_bib53","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/01.CIR.0000044388.19119.02","article-title":"Plasma urotensin in human systolic heart failure","volume":"106","author":"Ng","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.abb.2018.11.021_bib54","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(02)09709-X","article-title":"Plasma urotensin II in heart failure","volume":"360","author":"Richards","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.abb.2018.11.021_bib55","doi-asserted-by":"crossref","first-page":"H1576","DOI":"10.1152\/ajpheart.00217.2003","article-title":"Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure","volume":"285","author":"Russell","year":"2003","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.abb.2018.11.021_bib56","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.peptides.2007.12.018","article-title":"Increased gene expression of urotensin II-related peptide in the hearts of rats with congestive heart failure","volume":"29","author":"Nakayama","year":"2008","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.11.021_bib57","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.atherosclerosis.2004.03.023","article-title":"Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta","volume":"176","author":"Bousette","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.abb.2018.11.021_bib58","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1016\/j.peptides.2005.05.028","article-title":"Expression of urotensin-II in human coronary atherosclerosis","volume":"26","author":"Hassan","year":"2005","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.11.021_bib59","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1097\/01.hjh.0000125452.28861.f1","article-title":"Plasma concentration of urotensin II is raised in hypertension","volume":"22","author":"Cheung","year":"2004","journal-title":"J. Hypertens."},{"key":"10.1016\/j.abb.2018.11.021_bib60","doi-asserted-by":"crossref","first-page":"13876","DOI":"10.1038\/s41598-017-12613-y","article-title":"Urotensin II exerts pressor effects by stimulating renin and aldosterone synthase gene expression","volume":"7","author":"Caroccia","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.abb.2018.11.021_bib61","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.amjhyper.2006.08.001","article-title":"Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension","volume":"20","author":"Suguro","year":"2007","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.abb.2018.11.021_bib62","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.peptides.2007.06.005","article-title":"Another ligand fishing for G protein-coupled receptor 14. Discovery of urotensin II-related peptide in the rat brain","volume":"29","author":"Sugo","year":"2008","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.11.021_bib63","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ygcen.2012.02.018","article-title":"Characterization of the true ortholog of the urotensin II-related peptide (URP) gene in teleosts","volume":"177","author":"Quan","year":"2012","journal-title":"Gen. Comp. Endocrinol."},{"key":"10.1016\/j.abb.2018.11.021_bib64","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2174\/0929867043455495","article-title":"Recent structure-activity studies of the peptide hormone urotensin-II, a potent vasoconstrictor","volume":"11","author":"Grieco","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.abb.2018.11.021_bib65","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.peptides.2007.08.014","article-title":"Structure-activity relationships of urotensin II and URP","volume":"29","author":"Leprince","year":"2008","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.11.021_bib66","doi-asserted-by":"crossref","unstructured":"E. Billard, M. Iddir, H. Nassour, L. Lee-Gosselin, M. Poujol de Molliens, D. Chatenet, New directions for urotensin II receptor ligands. Peptides, ePub 9 March 2018, https:\/\/doi.org\/10.1002\/pep2.24056.","DOI":"10.1002\/pep2.24056"},{"key":"10.1016\/j.abb.2018.11.021_bib67","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1021\/ol060278h","article-title":"Design and synthesis of potent cystine-free cyclic hexapeptide agonists at the human urotensin receptor","volume":"8","author":"Foister","year":"2006","journal-title":"Org. Lett."},{"key":"10.1016\/j.abb.2018.11.021_bib68","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1021\/jm025549i","article-title":"A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge","volume":"45","author":"Grieco","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.abb.2018.11.021_bib69","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1002\/1521-3773(20020816)41:16<2940::AID-ANIE2940>3.0.CO;2-M","article-title":"Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model","volume":"41","author":"Kinney","year":"2002","journal-title":"Angew. Chem., Int. Ed. Engl."},{"key":"10.1016\/j.abb.2018.11.021_bib70","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1021\/jm0111043","article-title":"Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II","volume":"45","author":"Flohr","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.abb.2018.11.021_bib71","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/psc.590","article-title":"Structure-activity relationship study on human urotensin II","volume":"11","author":"Guerrini","year":"2005","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.abb.2018.11.021_bib72","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/sj.bjp.0704895","article-title":"A new ligand for the urotensin II receptor","volume":"137","author":"Camarda","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib73","first-page":"170","article-title":"The peptidic somatostatin analogs lanreotide, BIM-23127 and BIM-23042 are urotensin-II receptor ligands","volume":"44","author":"Herold","year":"2002","journal-title":"Pharmacologist"},{"key":"10.1016\/j.abb.2018.11.021_bib74","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/sj.bjp.0704887","article-title":"Pharmacological characterization of SB-710411 [Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpaamide], a novel peptidic urotensin-II receptor antagonist","volume":"137","author":"Behm","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib75","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/sj.bjp.0705555","article-title":"An ultrapotent urotensin II antagonist peptide in the rat aorta","volume":"140","author":"Patacchini","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib76","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejphar.2004.07.089","article-title":"Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors","volume":"498","author":"Camarda","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib77","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/sj.bjp.0706438","article-title":"In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II[4-11] [UFP-803]","volume":"147","author":"Camarda","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib78","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.bcp.2011.12.009","article-title":"Urocontrin, a novel UTreceptor ligand with a unique pharmacological profile","volume":"83","author":"Chatenet","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib79","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1080\/15321819.2017.1344130","article-title":"The role of human urotensin-II in patients with hypertrophic cardiomyopathy","volume":"39","author":"Jumaah","year":"2018","journal-title":"J. Immunoassay Immunochem."},{"key":"10.1016\/j.abb.2018.11.021_bib80","series-title":"Handbook of Biologically Active Peptides","first-page":"1428","author":"Richards","year":"2013"},{"key":"10.1016\/j.abb.2018.11.021_bib81","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/378287a0","article-title":"Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor","volume":"378","author":"Vaughan","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.abb.2018.11.021_bib82","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1073\/pnas.051626398","article-title":"Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors","volume":"98","author":"Reyes","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.abb.2018.11.021_bib83","doi-asserted-by":"crossref","first-page":"7570","DOI":"10.1073\/pnas.121165198","article-title":"Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor","volume":"98","author":"Lewis","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.abb.2018.11.021_bib84","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/87936","article-title":"Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor","volume":"7","author":"Hsu","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.abb.2018.11.021_bib85","doi-asserted-by":"crossref","first-page":"16102","DOI":"10.1021\/ja0760933","article-title":"Common and divergent structural features of a series of corticotropin releasing factor-related peptides","volume":"129","author":"Grace","year":"2007","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.abb.2018.11.021_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yfrne.2006.09.002","article-title":"Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs","volume":"28","author":"Fekete","year":"2007","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.abb.2018.11.021_bib87","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1210\/er.2005-0034","article-title":"The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology","volume":"27","author":"Hillhouse","year":"2006","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.abb.2018.11.021_bib88","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.2174\/092986711795933704","article-title":"Members of CRF family and their receptors: from past to future","volume":"18","author":"Liapakis","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.abb.2018.11.021_bib89","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1210\/jc.2003-031663","article-title":"Expression of urocortin III\/stresscopin in human heart and kidney","volume":"89","author":"Takahashi","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.abb.2018.11.021_bib90","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1210\/jcem.87.1.8160","article-title":"Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart","volume":"87","author":"Kimura","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.abb.2018.11.021_bib91","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S1734-1140(09)70019-2","article-title":"Urocortin: a protective peptide that targets both the myocardium and vasculature","volume":"61","author":"Davidson","year":"2009","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.abb.2018.11.021_bib92","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/0896-6273(93)90230-O","article-title":"Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain","volume":"11","author":"Chang","year":"1993","journal-title":"Neuron"},{"key":"10.1016\/j.abb.2018.11.021_bib93","doi-asserted-by":"crossref","first-page":"8967","DOI":"10.1073\/pnas.90.19.8967","article-title":"Expression cloning of a human corticotropin-releasing-factor receptor","volume":"90","author":"Chen","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.abb.2018.11.021_bib94","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1073\/pnas.92.7.2969","article-title":"Identification of a second CRF receptor gene and characterization of a cDNA expressed in heart","volume":"92","author":"Perrin","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.abb.2018.11.021_bib95","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1073\/pnas.92.3.836","article-title":"Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain","volume":"92","author":"Lovenberg","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.abb.2018.11.021_bib96","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0167-4781(97)00047-X","article-title":"A new functional isoform of the human CRF2 receptor for corticotropin- releasing factor","volume":"1352","author":"Valdenaire","year":"1997","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.abb.2018.11.021_bib97","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1210\/me.2002-0302","article-title":"Regulation of corticotropin-releasing hormone type 2 receptors by multiple promoters and alternative splicing: identification of multiple splice variants","volume":"17","author":"Catalano","year":"2003","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.abb.2018.11.021_bib98","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1210\/me.2005-0503","article-title":"Corticotropin-releasing hormone receptor CRHR1 and CRHR2 are both trafficking and signaling receptors for Urocortin","volume":"21","author":"Tu","year":"2007","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.abb.2018.11.021_bib99","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.peptides.2004.10.019","article-title":"Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity","volume":"26","author":"Hoare","year":"2005","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.11.021_bib100","doi-asserted-by":"crossref","first-page":"40351","DOI":"10.1074\/jbc.M110.186072","article-title":"Structural basis for hormone recognition by the human CRFR2\u03b1 g protein-coupled receptor","volume":"285","author":"Pal","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.abb.2018.11.021_bib101","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.peptides.2004.05.024","article-title":"Urocortins and corticotropin releasing factor type 2 receptors in the hypothalamus and the cardiovascular system","volume":"25","author":"Hashimoto","year":"2004","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.11.021_bib102","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/sj.bjp.0705985","article-title":"CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators","volume":"143","author":"Wiley","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib103","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijcard.2009.03.112","article-title":"Mechanisms of action and clinical implications of cardiac urocortin: a journey from the heart to the systemic circulation, with a stopover in the mitochondria","volume":"137","author":"Kuizon","year":"2009","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.abb.2018.11.021_bib104","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10557-013-6468-7","article-title":"Targeting urocortin signaling pathways to enhance cardioprotection: is it time to move from bench to bedside?","volume":"27","author":"Onorati","year":"2013","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.abb.2018.11.021_bib105","first-page":"753","article-title":"The role of urocortins in the cardiovascular system","volume":"65","author":"Walczewska","year":"2014","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib106","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cca.2017.09.003","article-title":"Urocortins: actions in health and heart failure","volume":"474","author":"Rademaker","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.abb.2018.11.021_bib107","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0167-0115(03)00003-X","article-title":"Intravenous urocortin II decreases blood pressure through CRF[2] receptor in rats","volume":"113","author":"Chen","year":"2003","journal-title":"Regul. Pept."},{"key":"10.1016\/j.abb.2018.11.021_bib108","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/HYPERTENSIONAHA.108.125211","article-title":"Immediate and sustained blood pressure lowering by urocortin 2 A novel approach to antihypertensive therapy?","volume":"53","author":"Dieterle","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.abb.2018.11.021_bib109","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/74255","article-title":"Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2","volume":"24","author":"Coste","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/j.abb.2018.11.021_bib110","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00005344-200310000-00015","article-title":"Vasodilative effects of urocortin II via protein kinase A and a mitogen-activated protein kinase in rat thoracic aorta","volume":"42","author":"Kageyama","year":"2003","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib111","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1161\/CIRCRESAHA.107.159053","article-title":"Role of Ca2+-independent phospholipase A2 and store-operated pathway in urocortin-induced vasodilatation of rat coronary artery","volume":"101","author":"Smani","year":"2007","journal-title":"Circ. Res."},{"key":"10.1016\/j.abb.2018.11.021_bib112","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.regpep.2004.03.019","article-title":"The relaxant effect of urocortin in rat pulmonary arteries","volume":"121","author":"Chan","year":"2004","journal-title":"Regul. Pept."},{"key":"10.1016\/j.abb.2018.11.021_bib113","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.bjp.0704587","article-title":"Urocortin-induced endothelium-dependent relaxation of rat coronary artery: role of nitric oxide and K+ channels","volume":"135","author":"Huang","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib114","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1677\/joe.0.1690177","article-title":"Coronary vasodilation and positive inotropism by urocortin in the isolated rat heart","volume":"169","author":"Terui","year":"2001","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.abb.2018.11.021_bib115","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.cardiores.2004.11.018","article-title":"Urocortin-induced relaxation in the human internal mammary artery","volume":"65","author":"Chen","year":"2005","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.abb.2018.11.021_bib116","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ejphar.2007.09.018","article-title":"The effect of urocortin II administration on the coronary circulation and cardiac function in the anaesthetized pig is nitricoxide- dependent","volume":"578","author":"Grossini","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib117","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.bbrc.2005.01.001","article-title":"Hypertrophic effects of urocortin homologous peptides are mediated via activation of the Akt pathway","volume":"328","author":"Chanalaris","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.abb.2018.11.021_bib118","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1006\/bbrc.1998.9297","article-title":"Urocortin, a newly identified corticotropin releasing factor-related mammalian peptide, stimulates atrial natriuretic peptide and brain natriuretic peptide secretions from neonatal rat cardiomyocytes","volume":"250","author":"Ikeda","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.abb.2018.11.021_bib119","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1006\/cyto.2001.1011","article-title":"Cardiotrophin-1 and Urocortin cause protection by the same pathway and hypertrophy via distinct pathways in cardiac myocytes","volume":"17","author":"Railson","year":"2002","journal-title":"Cytokine"},{"key":"10.1016\/j.abb.2018.11.021_bib120","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00380-011-0141-5","article-title":"Urocortin-induced cardiomyocytes hypertrophy is associated with regulation of the GSK-3\u03b2 pathway","volume":"27","author":"Gruson","year":"2012","journal-title":"Heart Ves."},{"key":"10.1016\/j.abb.2018.11.021_bib121","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1042\/CS20130425","article-title":"Urocortin 2 is associated with abdominal aortic aneurysm and mediates anti-proliferative effects on vascular smooth muscle cells via corticotrophin releasing factor receptor 2","volume":"126","author":"Emeto","year":"2014","journal-title":"Clin. Sci."},{"key":"10.1016\/j.abb.2018.11.021_bib122","doi-asserted-by":"crossref","first-page":"7734","DOI":"10.1073\/pnas.102187099","article-title":"Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization","volume":"99","author":"Bale","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.abb.2018.11.021_bib123","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/j.1476-5381.2009.00210.x","article-title":"Urocortin promotes the development of vasculitis in a rat model of thromboangiitis obliterans via corticotrophin-releasing factor type 1 receptors","volume":"157","author":"Xu","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib124","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1210\/en.2009-0489","article-title":"Local secretion of urocortin 1 promotes microvascular permeability during lipopolysaccharide-induced inflammation","volume":"150","author":"Cureton","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.abb.2018.11.021_bib125","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1476-5381.2009.00346.x","article-title":"Urocortin induced expression of COX-2 and ICAM-1 via corticotrophin-releasing factor type 2 receptor in rat aortic endothelial cells","volume":"158","author":"Zhang","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib126","doi-asserted-by":"crossref","first-page":"e110866","DOI":"10.1371\/journal.pone.0110866","article-title":"Vasoprotective effects of urocortin 1 against atherosclerosis in vitro and in vivo","volume":"9","author":"Hasegawa","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.abb.2018.11.021_bib127","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1210\/en.2003-0689","article-title":"Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart","volume":"145","author":"Brar","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.abb.2018.11.021_bib128","doi-asserted-by":"crossref","first-page":"8508","DOI":"10.1074\/jbc.275.12.8508","article-title":"Urocortin protects against ischemic and reperfusion injury via a MAPK- dependent pathway","volume":"275","author":"Brar","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.abb.2018.11.021_bib129","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1006\/jmcc.2002.1529","article-title":"Activation of protein kinase B\/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia\/reoxygenation-induced cell death","volume":"34","author":"Brar","year":"2002","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.abb.2018.11.021_bib130","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1152\/ajpheart.01135.2006","article-title":"Urocortin prevents mitochondrial permeability transition in response to reperfusion injury indirectly by reducing oxidative stress","volume":"293","author":"Townsend","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.abb.2018.11.021_bib131","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0735-1097(02)01930-7","article-title":"Urocortin promotes hemodynamic and bioenergetic recovery and improves cell survival in the isolated rat heart exposed to ischemia\/reperfusion","volume":"40","author":"Scarabelli","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.abb.2018.11.021_bib132","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ceca.2011.05.010","article-title":"Cardioprotective action of urocortin in postconditioning involves recovery of intracellular calcium handling","volume":"50","author":"Calderon-Sanchez","year":"2011","journal-title":"Cell Calcium"},{"key":"10.1016\/j.abb.2018.11.021_bib133","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1139\/y05-033","article-title":"In vivo protective effects of urocortin on ischemia-reperfusion injury in rat heart via free radical mechanisms","volume":"83","author":"Liu","year":"2005","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib134","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/FJC.0000000000000190","article-title":"Chronic urocortin 2 improves cardiac function and ameliorates cardiac remodeling after experimental myocardial infarction","volume":"65","author":"Ellmers","year":"2015","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib135","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3109\/07435800.2015.1094489","article-title":"Urocortin attenuates myocardial fibrosis in diabetic rats via the Akt\/GSK-3beta signaling pathway","volume":"41","author":"Liu","year":"2016","journal-title":"Endocr. Res."},{"key":"10.1016\/j.abb.2018.11.021_bib136","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/eurjhf\/hfq054","article-title":"Acute effects of Urocortin 2 on cardiac function and propensity for arrhythmias in an animal model of hypertension-induced left ventricular hypertrophy and heart failure","volume":"121","author":"Meili-Butz","year":"2010","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.abb.2018.11.021_bib137","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1073\/pnas.0307324101","article-title":"The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure","volume":"101","author":"Bale","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.abb.2018.11.021_bib138","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/hum.2014.157","article-title":"Intravenous AAV8 encoding urocortin-2 increases function of the failing heart in mice","volume":"26","author":"Lai","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.abb.2018.11.021_bib139","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1093\/eurheartj\/ehi227","article-title":"Endogenous urocortins reduce vascular tone and renin-aldosterone\/endothelin activity in experimental heart failure","volume":"26","author":"Rademaker","year":"2005","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.abb.2018.11.021_bib140","article-title":"Urocortin-2 improves right ventricular function in pulmonary arterial hypertension","author":"Santos -Ribeiro","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.abb.2018.11.021_bib141","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.peptides.2009.02.014","article-title":"Urocortin inhibits mesenteric arterial remodeling in spontaneously hypertensive rats","volume":"30","author":"Chen","year":"2009","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.11.021_bib142","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.pharep.2014.10.017","article-title":"The effects of vasoactive peptide urocortin 2 on hemodynamics in spontaneous hypertensive rat and the role of L-type calcium channel and CRFR2","volume":"67","author":"Liu","year":"2015","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.abb.2018.11.021_bib143","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1210\/jc.2003-031231","article-title":"Urocortin-1 infusion in normal humans","volume":"89","author":"Davis","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.abb.2018.11.021_bib144","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jacc.2006.09.035","article-title":"Urocortin 2 infusion in healthy humans: hemodynamic, neurohormonal, and renal responses","volume":"49","author":"Davis","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.abb.2018.11.021_bib145","doi-asserted-by":"crossref","first-page":"e004267","DOI":"10.1161\/JAHA.112.004267","article-title":"Vascular effects of urocortins 2 and 3 in healthy volunteers","volume":"2","author":"Venkatasubramanian","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.abb.2018.11.021_bib146","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/bcp.13033","article-title":"Cardiovascular effects of urocortin 2 and urocortin 3 in patients with chronic heart failure","volume":"82","author":"Stirrat","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib147","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1042\/CS20050079","article-title":"Effect of urocortin 1 infusion in humans with stable congestive cardiac failure","volume":"109","author":"Davis","year":"2005","journal-title":"Clin. Sci."},{"key":"10.1016\/j.abb.2018.11.021_bib148","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1093\/eurheartj\/ehm340","article-title":"Urocortin 2 infusion in human heart failure","volume":"28","author":"Davis","year":"2007","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.abb.2018.11.021_bib149","first-page":"433","article-title":"Urocortin-2 infusion in acute decompensated heart failure: findings from the UNICORN study (urocortin-2 in the treatment of acute heart failure as an adjunct over conventional therapy)","volume":"1","author":"Chan","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.abb.2018.11.021_bib150","first-page":"442","article-title":"The challenge of drug development in acute heart failure: balancing mechanisms, targeting patients, and gambling on outcomes","volume":"1","author":"Pang","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.abb.2018.11.021_bib151","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1084\/jem.20161924","article-title":"Corticotropin releasing hormone receptor 2 exacerbates chronic cardiac dysfunction","volume":"214","author":"Tsuda","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.abb.2018.11.021_bib152","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.yfrne.2013.10.006","article-title":"Corticotropin-releasing factor peptide antagonists: design, characterization and potential clinical relevance","volume":"35","author":"Rivier","year":"2014","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.abb.2018.11.021_bib153","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1021\/jm0613875","article-title":"Stressin1-A, a potent corticotropin releasing factor Receptor 1 (CRF1)-selective peptide agonist","volume":"50","author":"Rivier","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.abb.2018.11.021_bib154","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1021\/jm0202122","article-title":"Potent and long-acting Corticotropin Releasing Factor (CRF) Receptor 2 selective peptide competitive antagonists","volume":"45","author":"Rivier","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.abb.2018.11.021_bib155","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1021\/jm980426c","article-title":"Astressin analogues [CRF antagonists] with extended duration of action in the rat","volume":"41","author":"Rivier","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.abb.2018.11.021_bib156","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1126\/science.6326264","article-title":"Synthetic competitive antagonists of corticotropin releasing factor: effect on ACTH secretion in the rat","volume":"224","author":"Rivier","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.abb.2018.11.021_bib157","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1021\/jm00072a003","article-title":"Single point D-substituted corticotropin-releasing factor analogues: effects on potency and physicochemical characteristics","volume":"36","author":"Rivier","year":"1993","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.abb.2018.11.021_bib158","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1021\/jm00072a004","article-title":"Synthesis and relative potencies of new constrained CRF antagonists","volume":"36","author":"Hernandez","year":"1993","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.abb.2018.11.021_bib159","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1021\/jm980350k","article-title":"J. Rivier. Constrained corticotropin-releasing factor (CRF) agonists and antagonists with i-(i+3) Glu-Xaa-DXbb-Lys bridges","volume":"41","author":"Koerber","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.abb.2018.11.021_bib160","doi-asserted-by":"crossref","first-page":"15264","DOI":"10.1073\/pnas.95.26.15264","article-title":"Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2 \u03b2-selective antisauvagine-30","volume":"95","author":"R\u00fchmann","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.abb.2018.11.021_bib161","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1021\/jm049883l","article-title":"Determinants of corticotropin releasing factor. Receptor selectivity of corticotropin releasing factor related peptides","volume":"47","author":"Mazur","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.abb.2018.11.021_bib162","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.peptides.2004.12.013","article-title":"Sauvagine analogs selective for corticotropin releasing factor 2 receptor: effect of substitutions at positions 35 and 39 on CRF2R selectivity","volume":"26","author":"Mazur","year":"2005","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.11.021_bib163","unstructured":"M. Chen, K-F. Lee, C. Li, W.W. Vale, Methods of Increasing Insulin Sensitivity or Decreasing Insulin Secretion by Administering Corticotropin Releasing Factor Receptor-2 Inhibitors US 7,815,905 B2, 2010."},{"key":"10.1016\/j.abb.2018.11.021_bib164","unstructured":"W. W. Vale Jr, K. A. Lewis, M. H. Perrin, K. Kunitake, J. E. F. Rivier, J. Gulyas, Urocortin-III and uses thereof US 9,388,229 B2, 2016."},{"key":"10.1016\/j.abb.2018.11.021_bib165","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1111\/j.1476-5381.2012.01904.x","article-title":"Pharmacokinetics and pharmacodynamics of urocortins 1, 2 and 3 in healthy sheep","volume":"166","author":"Patel","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib166","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.peptides.2006.01.003","article-title":"Modifications of the human urocortin 2 peptide that improve pharmacological properties","volume":"27","author":"Isfort","year":"2006","journal-title":"Peptides"},{"issue":"866 B2","key":"10.1016\/j.abb.2018.11.021_bib167","first-page":"572","article-title":"Urocortin 2 analogs and uses thereof","volume":"9","author":"Vale","year":"2017","journal-title":"U. S. Jpn. Outlook"},{"key":"10.1016\/j.abb.2018.11.021_bib168","unstructured":"J. Alsina-Fernandez, L. Guo, J. Lee. Novel Fatty Acid Modified Urocortin-2 Analogs for the Treatment of Diabetes and Chronic Kidney Disease US 2018\/0016318 A1, 2018."},{"key":"10.1016\/j.abb.2018.11.021_bib169","first-page":"249","article-title":"Effects of urocortin 2 versus urocortin 3 gene transfer on left ventricular function and glucose disposal","volume":"3","author":"Giamouridis","year":"2018","journal-title":"J. Am. Coll. Cardiol. Basic Trans Sci."},{"key":"10.1016\/j.abb.2018.11.021_bib170","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1042\/CS20030311","article-title":"Plasma urocortin in human systolic heart failure","volume":"106","author":"Ng","year":"2004","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.abb.2018.11.021_bib171","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/CIRCHEARTFAILURE.108.840207","article-title":"Plasma urocortin 1 in human heart failure","volume":"2","author":"Wright","year":"2009","journal-title":"Circ. Heart Fail"},{"key":"10.1016\/j.abb.2018.11.021_bib172","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.peptides.2009.11.023","article-title":"Circulating levels of stress associated peptide Urocortin in heart failure patients","volume":"31","author":"Gruson","year":"2010","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.11.021_bib173","doi-asserted-by":"crossref","first-page":"452","DOI":"10.5603\/KP.a2013.0353","article-title":"Evaluation of \u2028the clinical utility of urocortin 1 in systolic heart failure","volume":"72","author":"Yildirim","year":"2014","journal-title":"Kardiol. Pol."},{"key":"10.1016\/j.abb.2018.11.021_bib174","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.1365-2362.2010.02343.x","article-title":"Plasma urocortin in acute myocardial infarction","volume":"40","author":"Phrommintikul","year":"2010","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.abb.2018.11.021_bib175","first-page":"115","article-title":"Relationship of urocortin-2 with systolic and diastolic functions and coronary artery disease: an observational study","volume":"12","author":"Topal","year":"2012","journal-title":"Anadolu Kardiyol. Derg."},{"key":"10.1016\/j.abb.2018.11.021_bib176","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1373\/clinchem.2015.252932","article-title":"High-sensitivity sandwich ELISA for plasma NT-proUcn2: plasma concentrations and relationship to mortality in heart failure","volume":"62","author":"Liew","year":"2016","journal-title":"Clin. Chem."},{"key":"10.1016\/j.abb.2018.11.021_bib177","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1210\/en.2016-1448","article-title":"Cardiac CRFR1 expression is elevated in human heart failure and modulated by genetic variation and alternative splicing","volume":"157","author":"Pilbrow","year":"2016","journal-title":"Endocrinology"},{"key":"10.1016\/j.abb.2018.11.021_bib178","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.jtcvs.2014.05.018","article-title":"Diabetic hearts have lower basal urocortin levels that fail to increase after cardioplegic arrest: association with increased apoptosis and postsurgical cardiac dysfunction","volume":"148","author":"Chen-Scarabelli","year":"2014","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.abb.2018.11.021_bib179","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1006\/bbrc.1993.1451","article-title":"Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma","volume":"192","author":"Kitamura","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.abb.2018.11.021_bib180","series-title":"Hand-book of Biologically Active Peptides","first-page":"1361","article-title":"Adrenomedullin peptides","author":"Kato","year":"2013"},{"key":"10.1016\/j.abb.2018.11.021_bib181","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF01457408","article-title":"Immunohistochemical identification of adrenomedullin in human, rat, and porcine tissue","volume":"103","author":"Washimine","year":"1995","journal-title":"Histochem. Cell Biol."},{"key":"10.1016\/j.abb.2018.11.021_bib182","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1006\/bbrc.1994.2229","article-title":"Genomic structure of human adrenomedullin gene","volume":"203","author":"Ishimitsu","year":"1994","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.abb.2018.11.021_bib183","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1006\/bbrc.1993.1881","article-title":"Cloning and characterization of cDNA encoding a precursor for human adrenomedullin","volume":"194","author":"Kitamura","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.abb.2018.11.021_bib184","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1615\/CritRevNeurobiol.v11.i2-3.40","article-title":"Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily","volume":"11","author":"Wimalawansa","year":"1997","journal-title":"Crit. Rev. Neurobiol."},{"key":"10.1016\/j.abb.2018.11.021_bib185","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0014-5793(03)01368-1","article-title":"Identification of novel adrenomedullin in mammals: a potent cardiovascular and renal regulator","volume":"556","author":"Takei","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.abb.2018.11.021_bib186","doi-asserted-by":"crossref","first-page":"7264","DOI":"10.1074\/jbc.M305332200","article-title":"Intermedin is a calcitonin\/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor\/receptor activity modifying protein receptor complexes","volume":"279","author":"Roh","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.abb.2018.11.021_bib187","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0304-3940(95)12294-X","article-title":"Immunocytochemical localization of adrenomedullin-like immunoreactivity in the human hypothalamus and the adrenal gland","volume":"203","author":"Satoh","year":"1996","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.abb.2018.11.021_bib188","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0196-9781(97)00038-7","article-title":"Expression of adrenomedullin mRNA in the human brain and pituitary","volume":"18","author":"Takahashi","year":"1997","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.11.021_bib189","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/0014-5793(94)80106-1","article-title":"Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma","volume":"338","author":"Ichiki","year":"1994","journal-title":"FEBS Lett."},{"key":"10.1016\/j.abb.2018.11.021_bib190","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0167-0115(03)00023-5","article-title":"Regulation of production and secretion of adrenomedullin in the cardiovascular system","volume":"112","author":"Eto","year":"2003","journal-title":"Regul. Pept."},{"key":"10.1016\/j.abb.2018.11.021_bib191","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1006\/bbrc.1993.1881","article-title":"Cloning and characterization of cDNA encoding a precursor for human adrenomedullin","volume":"194","author":"Kitamura","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.abb.2018.11.021_bib192","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0008-6363(00)00291-1","article-title":"Cardiac fibroblasts are major production and target cells of adrenomedullin in the heart in vitro","volume":"49","author":"Tomoda","year":"2001","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.abb.2018.11.021_bib193","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1006\/bbrc.1994.1827","article-title":"Endothelial cells actively synthesize and secrete adrenomedullin","volume":"201","author":"Minamino","year":"1994","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.abb.2018.11.021_bib194","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1006\/bbrc.1994.2241","article-title":"Production and secretion of adrenomedullin from vascular smooth muscle cells: augmented production by tumor necrosis factor-alpha","volume":"203","author":"Sugo","year":"1994","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.abb.2018.11.021_bib195","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0167-0115(03)00037-5","article-title":"Adrenomedullin and cancer","volume":"112","author":"Zudaire","year":"2003","journal-title":"Regul. Pept."},{"key":"10.1016\/j.abb.2018.11.021_bib196","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.pharmthera.2004.07.002","article-title":"The clinical relevance of adrenomedullin: a promising profile?","volume":"103","author":"Bunton","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.abb.2018.11.021_bib197","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1189\/jlb.0206123","article-title":"The central role of adrenomedullin in host defense","volume":"80","author":"Zudaire","year":"2006","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.abb.2018.11.021_bib198","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejphar.2015.06.061","article-title":"Bench-to-bedside pharmacology of adrenomedullin","volume":"764","author":"Kato","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib199","first-page":"30061","article-title":"Adrenomedullin: continuing to explore cardioprotection","volume":"18","author":"Tsuruda","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.11.021_bib200","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1124\/pr.54.2.233","article-title":"The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors","volume":"54","author":"Poyner","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.abb.2018.11.021_bib201","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/30666","article-title":"RAMPs regulate the transport and ligand specificity of the calcitoni n-receptor-like receptor","volume":"393","author":"McLatchie","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.abb.2018.11.021_bib202","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0014-5793(99)00358-0","article-title":"The RAMP2\/CRLR complex is a functional adrenomedullin receptor in human endothelial and vascular smooth muscle cells","volume":"448","author":"Kamitani","year":"1999","journal-title":"FEBS Lett."},{"key":"10.1016\/j.abb.2018.11.021_bib203","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bph.14075","article-title":"Update on the pharmacology of calcitonin\/CGRP family of peptides","volume":"175","author":"Hay","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib204","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1128\/MCB.26.7.2511-2518.2006","article-title":"Hydrops fetalis, cardiovascular defects, and embryonic lethality in mice lacking the calcitonin receptor-like receptor gene","volume":"26","author":"Dackor","year":"2006","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.abb.2018.11.021_bib205","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1172\/JCI33022","article-title":"The GPCR modulator protein RAMP2 is essential for angiogenesis and vascular integrity","volume":"118","author":"Ichikawa-Shindo","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.abb.2018.11.021_bib206","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1073\/pnas.98.2.615","article-title":"Extreme hydrops fetalis and cardiovascular abnormalities in mice lacking a functional Adrenomedullin gene","volume":"98","author":"Caron","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.abb.2018.11.021_bib207","doi-asserted-by":"crossref","first-page":"18094","DOI":"10.1074\/jbc.M703544200","article-title":"Receptor activity-modifying proteins 2 and 3 have distinct physiological functions from embryogenesis to old age","volume":"282","author":"Dackor","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.abb.2018.11.021_bib208","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.yjmcc.2014.09.017","article-title":"Functional differentiation of RAMP2 and RAMP3 in their regulation of the vascular system","volume":"77","author":"Yamauchi","year":"2014","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.abb.2018.11.021_bib209","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1006\/bbrc.2001.5572","article-title":"Effects of endothelin on adrenomedullin secretion and expression of adrenomedullin receptors in rat cardiomyocytes","volume":"287","author":"Mishima","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.abb.2018.11.021_bib210","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1210\/endo.136.5.7720662","article-title":"An abundant and specific binding site for the novel vasodilator adrenomedullin in the rat","volume":"136","author":"Owji","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/j.abb.2018.11.021_bib211","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.bjp.0702975","article-title":"CGRP and adrenomedullin binding correlates with transcript levels for calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) in rat tissues","volume":"130","author":"Chakravarty","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib212","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0304-3940(00)01706-7","article-title":"Adrenomedullin receptors in rat choroid plexus","volume":"297","author":"Kobayashi","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.abb.2018.11.021_bib213","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0014-5793(99)00358-0","article-title":"The RAMP2\/CRLR complex is a functional adrenomedullin receptor in human endothelial and vascular smooth muscle cells","volume":"448","author":"Kamitani","year":"1999","journal-title":"FEBS Lett."},{"key":"10.1016\/j.abb.2018.11.021_bib214","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1006\/bbrc.1993.2241","article-title":"Vasodilator effect of AM and CGRP receptors in rat mesenteric vascular beds","volume":"196","author":"Nuki","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.abb.2018.11.021_bib215","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/01.CIR.95.5.1214","article-title":"The vasodilatory potency of adrenomedullin in human forearm vascular bed","volume":"95","author":"Nakamura","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.abb.2018.11.021_bib216","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0014-2999(93)90214-3","article-title":"Hemodynamic effects of a novel hypotensive peptide, human adrenomedullin, in rats","volume":"241","author":"Ishiyama","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib217","first-page":"R716","article-title":"Vasodilation and glomerular binding of adrenomedullin in rabbit kidney are not CGRP receptor mediated","volume":"42","author":"Hjelmqvist","year":"1997","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.abb.2018.11.021_bib218","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0006-291X(02)00821-5","article-title":"Hemodynamic effects of exogenous adrenomedullin in healthy and endotoxemic sheep","volume":"296","author":"Westphal","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.abb.2018.11.021_bib219","first-page":"H2620","article-title":"Human coronary arteriolar dilation to adrenomedullin: role of nitric oxide and K[+] channels","volume":"279","author":"Terata","year":"2000","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.abb.2018.11.021_bib220","doi-asserted-by":"crossref","first-page":"L251","DOI":"10.1016\/0024-3205(94)00246-0","article-title":"Synthetic human adrenomedullin and AM15\u201352 have potent short-lasting vasodilator activity in the pulmonary vascular bed of the cat","volume":"55","author":"Cheng","year":"1994","journal-title":"Life Sci."},{"key":"10.1016\/j.abb.2018.11.021_bib221","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1152\/jappl.1994.76.5.2154","article-title":"Adrenomedullin dilates the pulmonary vascular bed in vivo","volume":"76","author":"Lippton","year":"1994","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.abb.2018.11.021_bib222","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1291\/hypres.26.S141","article-title":"Pulmonary vasodilator response to adrenomedullin in patients with pulmonary hypertension","volume":"26","author":"Nagaya","year":"2003","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.abb.2018.11.021_bib223","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00004872-199602000-00009","article-title":"Adrenomedullin as a novel antiproliferative factor of vascular smooth muscle cells","volume":"14","author":"Kano","year":"1996","journal-title":"J. Hypertens."},{"key":"10.1016\/j.abb.2018.11.021_bib224","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1161\/01.HYP.36.1.83","article-title":"Adrenomedullin and nitric oxide inhibit human endothelial cell apoptosis via a cyclic GMP-independent mechanism","volume":"36","author":"Sata","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.abb.2018.11.021_bib225","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0014-5793(03)00484-8","article-title":"Adrenomedullin provokes endothelial Akt activation and promotes vascular regeneration both in vitro and in vivo","volume":"544","author":"Miyashita","year":"2003","journal-title":"FEBS Lett."},{"key":"10.1016\/j.abb.2018.11.021_bib226","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejphar.2004.12.019","article-title":"Adrenomedullin alleviates not only neointimal formation but also perivascular hyperplasia following arterial injury in rats","volume":"508","author":"Tsuruda","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib227","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1161\/01.ATV.0000024685.92243.E7","article-title":"Resistance to neointimal hyperplasia and fatty streak formation in mice with adrenomedullin overexpression","volume":"22","author":"Imai","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.abb.2018.11.021_bib228","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0014-2999(98)00475-0","article-title":"Chronic infusion of adrenomedullin reduces pulmonary hypertension and lessens right ventricular hypertrophy in rats administered monocrotaline","volume":"355","author":"Yoshihara","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib229","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1006\/bbrc.1994.1496","article-title":"Adrenomedullin stimulates cyclic AMP formation in rat vascular smooth muscle cells","volume":"200","author":"Ishizaka","year":"1994","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.abb.2018.11.021_bib230","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1074\/jbc.270.9.4412","article-title":"Adrenomedullin stimulates two signal transduction pathways, cAMP accumulation and Ca 2+ mobilization, in bovine aortic endothelial cells","volume":"270","author":"Shimekake","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.abb.2018.11.021_bib231","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0014-2999(98)00641-4","article-title":"Adrenomedullin synergistically interacts with endogenous vasodilators in rats: a possible role of K(ATP) channels","volume":"359","author":"Sakai","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib232","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/sj.bjp.0705572","article-title":"Direct coronary vasodilator action of adrenomedullin is mediated by nitric oxide","volume":"140","author":"De Matteo","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib233","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1161\/hh1301.092498","article-title":"Adrenomedullin induces endothelium-dependent vasorelaxation via the phosphatidylinositol 3-kinase\/Akt-dependent pathway in rat aorta","volume":"89","author":"Nishimatsu","year":"2001","journal-title":"Circ. Res."},{"key":"10.1016\/j.abb.2018.11.021_bib234","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/01.HYP.31.1.505","article-title":"Adrenomedullin: a possible autocrine or paracrine inhibitor of hypertrophy of cardiomyocytes","volume":"31","author":"Tsuruda","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.abb.2018.11.021_bib235","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0008-6363(99)00122-4","article-title":"An autocrine or a paracrine role of adrenomedullin in modulating cardiac fibroblast growth","volume":"43","author":"Tsuruda","year":"1999","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.abb.2018.11.021_bib236","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1161\/01.CIR.0000136085.34185.83","article-title":"Adrenomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats","volume":"110","author":"Nakamura","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.abb.2018.11.021_bib237","doi-asserted-by":"crossref","first-page":"H1506","DOI":"10.1152\/ajpheart.00270.2003","article-title":"Adrenomedullin gene delivery attenuates myocardial infarction and apoptosis after ischemia and reperfusion","volume":"285","author":"Kato","year":"2003","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.abb.2018.11.021_bib238","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/01.CIR.0000109214.30211.7C","article-title":"Adrenomedullin infusion attenuates myocardial ischemia\/reperfusion injury through the phosphatidylinositol 3-kinase\/Akt-dependent pathway","volume":"109","author":"Okumura","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.abb.2018.11.021_bib239","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.yjmcc.2006.05.017","article-title":"A critical cytoprotective role of endogenous adrenomedullin in acute myocardial infarction","volume":"41","author":"Hamid","year":"2006","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.abb.2018.11.021_bib240","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1096\/fj.02-1209fje","article-title":"Angiogenic role of adrenomedullin through activation of Akt, mitogen-activated protein kinase, and focal adhesion kinase in endothelial cells","volume":"17","author":"Kim","year":"2003","journal-title":"Faseb. J."},{"key":"10.1016\/j.abb.2018.11.021_bib241","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1161\/CIRCULATIONAHA.112.000756","article-title":"Vascular endothelial adrenomedullin-RAMP2 system is essential for vascular integrity and organ homeostasis","volume":"127","author":"Koyama","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.abb.2018.11.021_bib242","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1161\/hc4101.097111","article-title":"Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene","volume":"104","author":"Shindo","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.abb.2018.11.021_bib243","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1096\/fj.02-1209fje","article-title":"Angiogenic role of adrenomedullin through activation of Akt, mitogen-activated protein kinase, and focal adhesion kinase in endothelial cells","volume":"17","author":"Kim","year":"2003","journal-title":"Faseb. J."},{"key":"10.1016\/j.abb.2018.11.021_bib244","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1161\/01.CIR.0000153352.29335.B9","article-title":"Adrenomedullin enhances angiogenic potency of bone marrow transplantation in a rat model of hindlimb ischemia","volume":"111","author":"Iwase","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.abb.2018.11.021_bib245","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/cvr\/cvn228","article-title":"Adrenomedullin induces lymph angiogenesis and ameliorates secondary lymphedema","volume":"80","author":"Jin","year":"2008","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.abb.2018.11.021_bib246","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejphar.2015.06.061","article-title":"Bench-to-bedside pharmacology of adrenomedullin","volume":"764","author":"Kato","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib247","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1046\/j.1365-2125.1997.00622.x","article-title":"Haemodynamic effects of adrenomedullin in human resistance and capacitance vessels","volume":"44","author":"Cockcroft","year":"1997","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib248","first-page":"1016","article-title":"Hemodynamic, hormonal, and renal effects of short-term adrenomedullin infusion in healthy volunteers","volume":"85","author":"Lainchbury","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.abb.2018.11.021_bib249","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2281.2000.00284.x","article-title":"Effects of low-dose adrenomedullin on cardiac function and systemic haemodynamics in man","volume":"20","author":"Del Bene","year":"2000","journal-title":"Clin. Physiol."},{"key":"10.1016\/j.abb.2018.11.021_bib250","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.0306-5251.2001.1420.x","article-title":"Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP)","volume":"52","author":"Wilkinson","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib251","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1161\/01.CIR.101.5.498","article-title":"Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure","volume":"101","author":"Nagaya","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.abb.2018.11.021_bib252","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1253\/circj.CJ-08-0487","article-title":"Effects of long-term intravenous administration of adrenomedullin (AM) plus hANP therapy in acute decompensated heart failure: a pilot study","volume":"73","author":"Nishikimi","year":"2009","journal-title":"Circ. J."},{"key":"10.1016\/j.abb.2018.11.021_bib253","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1097\/00005344-200205000-00017","article-title":"Intravenous adrenomedullin in myocardial function and energy metabolism in patients after myocardial infarction","volume":"39","author":"Nagaya","year":"2002","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib254","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/FJC.0b013e3181f15b45","article-title":"The first clinical pilot study of intravenous adrenomedullin administration in patients with acute myocardial infarction","volume":"56","author":"Kataoka","year":"2010","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib255","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/heart.84.6.653","article-title":"Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension","volume":"84","author":"Nagaya","year":"2000","journal-title":"Heart"},{"key":"10.1016\/j.abb.2018.11.021_bib256","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1161\/01.CIR.0000109493.05849.14","article-title":"Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension","volume":"109","author":"Nagaya","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.abb.2018.11.021_bib257","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/psc.2953","article-title":"Adrenomedullin \u2013 new perspectives of a potent peptide hormone","volume":"23","author":"Sch\u00f6nauer","year":"2017","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.abb.2018.11.021_bib258","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/endo.135.6.7988431","article-title":"Structure-activity relationship of adrenomedullin, a novel vasodilatory peptide, in cultured rat vascular smooth muscle cells","volume":"135","author":"Eguchi","year":"1994","journal-title":"Endocrinology"},{"key":"10.1016\/j.abb.2018.11.021_bib259","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3109\/07435809809032677","article-title":"Structure\u2013activity relationships of adrenomedullin in the adrenal gland","volume":"24","author":"Belloni","year":"1998","journal-title":"Endocr. Res."},{"key":"10.1016\/j.abb.2018.11.021_bib260","doi-asserted-by":"crossref","first-page":"PL85","DOI":"10.1016\/0024-3205(94)00652-0","article-title":"Synthetic human adrenomedullin and adrenomedullin 15-52 have potent short-lived vasodilator activity in the hindlimb vascular bed of the cat","volume":"55","author":"Santiago","year":"1994","journal-title":"Life Sci."},{"key":"10.1016\/j.abb.2018.11.021_bib261","doi-asserted-by":"crossref","first-page":"PL265","DOI":"10.1016\/0024-3205(94)00844-2","article-title":"An adrenomedullin (ADM) fragment retains the systemic vasodilator activity of human ADM","volume":"54","author":"Hao","year":"1994","journal-title":"Life Sci."},{"key":"10.1016\/j.abb.2018.11.021_bib262","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0014-2999(94)00693-2","article-title":"Comparison of responses to adrenomedullin and adrenomedullin analogs in the mesenteric vascular bed of the cat","volume":"272","author":"Santiago","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib263","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1161\/01.HYP.28.6.1041","article-title":"Catecholamine release mediates pressor effects of Adrenomedullin-(15-22) in the rat","volume":"28","author":"Champion","year":"1996","journal-title":"Hypertension"},{"key":"10.1016\/j.abb.2018.11.021_bib264","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1006\/bbrc.1996.0181","article-title":"Vasopressor activities of N-terminal fragments of adrenomedullin in anesthetized rat","volume":"219","author":"Watanabe","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.abb.2018.11.021_bib265","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0196-9781(01)00529-0","article-title":"Adrenomedullin (11-26): a novel endogenous hypertensive peptide isolated from bovine adrenal medulla","volume":"22","author":"Kitamura","year":"2001","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.11.021_bib266","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1124\/jpet.109.156448","article-title":"Novel peptide antagonists of adrenomedullin and calcitonin gene-related peptide receptors: identification, pharmacological characterization, and interactions with position 74 in receptor activity-modifying protein 1\/3","volume":"331","author":"Robinson","year":"2009","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.abb.2018.11.021_bib267","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.bjp.0705472","article-title":"CL\/RAMP2 and CL\/RAMP3 produce pharmacologically distinct adrenomedullin receptors: a comparison of effects of adrenomedullin 22-52, CGRP8-37 and BIBN4096BS","volume":"140","author":"Hay","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib268","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/bph.12118","article-title":"Identification of key residues involved in adrenomedullin binding to the AM1 receptor","volume":"169","author":"Watkins","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib269","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/pro.2377","article-title":"Selective CGRP and adrenomedullin peptide binding by tethered RAMP-calcitonin receptor-like receptor extracellular domain fusion proteins","volume":"22","author":"Moad","year":"2013","journal-title":"Protein Sci."},{"key":"10.1016\/j.abb.2018.11.021_bib270","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.molcel.2015.04.018","article-title":"Structural basis for receptor activity-modifying protein dependent selective peptide recognition by a G protein-coupled receptor","volume":"58","author":"Booe","year":"2015","journal-title":"Mol. Cell."},{"key":"10.1016\/j.abb.2018.11.021_bib271","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.str.2010.05.014","article-title":"Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism","volume":"18","author":"ter Haar","year":"2010","journal-title":"Structure"},{"key":"10.1016\/j.abb.2018.11.021_bib272","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/bph.12508","article-title":"Receptor activity-modifying protein-dependent effects of mutations in the calcitonin receptor-like receptor: implications for adrenomedullin and calcitonin gene-related peptide pharmacology","volume":"171","author":"Watkins","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib273","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.peptides.2011.03.004","article-title":"Structure\u2013 function analysis of amino acid 74 of human RAMP1 and RAMP3 and its role in peptide interactions with adrenomedullin and calcitonin gene-related peptide receptors","volume":"32","author":"Qi","year":"2011","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.11.021_bib274","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1124\/mol.117.110916","article-title":"Probing the mechanism of receptor activity\u2013modifying protein modulation of GPCR ligand selectivity through rational design of potent adrenomedullin and calcitonin gene-related peptide antagonists","volume":"93","author":"Booe","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.abb.2018.11.021_bib275","doi-asserted-by":"crossref","first-page":"11657","DOI":"10.1074\/jbc.M115.688218","article-title":"Receptor activity-modifying proteins 2 and 3 generate adrenomedullin receptor subtypes with distinct molecular properties","volume":"291","author":"Watkins","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.abb.2018.11.021_bib276","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.1021\/acs.jmedchem.6b00126","article-title":"Adrenomedullin 2.0: adjusting key levers for metabolic stability","volume":"59","author":"Sch\u00f6nauer","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.abb.2018.11.021_bib277","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.peptides.2014.05.005","article-title":"Biological properties of adrenomedullin conjugated with polyethylene glycol","volume":"57","author":"Kubo","year":"2014","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.11.021_bib278","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ddr.21383","article-title":"Anti-inflammatory effects of PEGylated human adrenomedullin in a mouse DSS-induced colitis model","volume":"78","author":"Nagata","year":"2017","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.abb.2018.11.021_bib279","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1210\/en.2003-1251","article-title":"Identification of vasoactive nonpeptidic positive and negative modulators of adrenomedullin using a neutralizing antibody-based screening strategy","volume":"145","author":"Mart\u00ednez","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.abb.2018.11.021_bib280","doi-asserted-by":"crossref","first-page":"17488","DOI":"10.1038\/s41598-017-17573-x","article-title":"Small molecules related to adrenomedullin reduce tumor burden in a mouse model of colitis-associated colon cancer","volume":"7","author":"Ochoa-Callejero","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.abb.2018.11.021_bib281","first-page":"95","article-title":"Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study","volume":"82","author":"Meeran","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.abb.2018.11.021_bib282","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1161\/01.HYP.36.6.995","article-title":"Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats","volume":"36","author":"Dobrzynski","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.abb.2018.11.021_bib283","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0196-9781(01)00510-1","article-title":"Human adrenomedullin gene delivery protects against cardiovascular remodeling and renal injury","volume":"22","author":"Chao","year":"2001","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.11.021_bib284","doi-asserted-by":"crossref","first-page":"F964","DOI":"10.1152\/ajprenal.2001.280.6.F964","article-title":"Adrenomedullin gene delivery attenuates renal damage and cardiac hypertrophy in Goldblatt hypertensive rats","volume":"280","author":"Wang","year":"2001","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"10.1016\/j.abb.2018.11.021_bib285","doi-asserted-by":"crossref","first-page":"E1291","DOI":"10.1152\/ajpendo.00147.2002","article-title":"Adrenomedullin improves cardiac function and prevents renal damage in streptozotocin-induced diabetic rats","volume":"283","author":"Dobrzynski","year":"2002","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.abb.2018.11.021_bib286","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1159\/000320562","article-title":"Adrenomedullin gene delivery is cardio-protective in a model of chronic nitric oxide deficiency combining pressure overload, oxidative stress and cardiomyocyte hypertrophy","volume":"26","author":"Bell","year":"2010","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.abb.2018.11.021_bib287","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/jgm.1219","article-title":"Adaptive or maladaptive response to adenoviral adrenomedullin gene transfer is context-dependent in the heart","volume":"10","author":"Leskinen","year":"2008","journal-title":"J. Gene Med."},{"key":"10.1016\/j.abb.2018.11.021_bib288","article-title":"Vascular effects of adrenomedullin and the anti-adrenomedullin antibody Adrecizumab in sepsis","author":"Geven","year":"2018","journal-title":"Shock"},{"key":"10.1016\/j.abb.2018.11.021_bib289","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.hfc.2017.08.006","article-title":"Adrenomedullin as a biomarker of heart failure","volume":"14","author":"Nishikimi","year":"2018","journal-title":"Heart Fail. Clin."},{"key":"10.1016\/j.abb.2018.11.021_bib290","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1172\/JCI117573","article-title":"Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure","volume":"94","author":"Ishimitsu","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.abb.2018.11.021_bib291","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S0002-8703(96)90185-4","article-title":"Increased plasma adrenomedullin levels in chronic congestive heart failure","volume":"131","author":"Kobayashi","year":"1996","journal-title":"Am. Heart J."},{"key":"10.1016\/j.abb.2018.11.021_bib292","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/hrt.79.1.39","article-title":"Increased plasma adrenomedullin levels in patients with acute myocardial infarction in proportion to the clinical severity","volume":"79","author":"Miyao","year":"1998","journal-title":"Heart"},{"key":"10.1016\/j.abb.2018.11.021_bib293","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1291\/hypres.26.887","article-title":"Plasma adrenomedullin is closely correlated with pulse wave velocity in middle-aged and elderly patients","volume":"26","author":"Kita","year":"2003","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.abb.2018.11.021_bib294","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0196-9781(01)00507-1","article-title":"Association of plasma adrenomedullin with carotid atherosclerosis in chronic ischemic stroke","volume":"22","author":"Shinomiya","year":"2001","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.11.021_bib295","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.regpep.2003.11.001","article-title":"Plasma adrenomedullin concentration is increased in patients with peripheral arterial occlusive disease associated with vascular inflammation","volume":"118","author":"Suzuki","year":"2004","journal-title":"Regul. Pept."},{"key":"10.1016\/j.abb.2018.11.021_bib296","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1006\/bbrc.1998.8310","article-title":"The intermediate form of glycine-extended adrenomedullin is the major circulating molecular form in human plasma","volume":"244","author":"Kitamura","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.abb.2018.11.021_bib297","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0009-8981(99)00128-X","article-title":"A simple immunoradiometric assay for measuring the entire molecules of adrenomedullin in human plasma","volume":"287","author":"Ohta","year":"1999","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.abb.2018.11.021_bib298","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/clinchem\/45.2.244","article-title":"One- step direct assay for mature-type adrenomedullin with monoclonal antibodies","volume":"45","author":"Ohta","year":"1999","journal-title":"Clin. Chem."},{"key":"10.1016\/j.abb.2018.11.021_bib299","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.peptides.2007.12.006","article-title":"Plasma adrenomedullin as an independent predictor of future cardiovascular events in high-risk patients: comparison with C-reactive protein and adiponectin","volume":"29","author":"Nishida","year":"2008","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.11.021_bib300","doi-asserted-by":"crossref","first-page":"329","DOI":"10.21037\/atm.2016.08.65","article-title":"New role of biomarkers: mid-regional pro-adrenomedullin, the biomarker of organ failure","volume":"4","author":"Valenzuela-S\u00e1nchez","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.abb.2018.11.021_bib301","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13613-016-0229-2","article-title":"Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shock","volume":"7","author":"Tolppanen","year":"2017","journal-title":"Ann. Intensive Care"},{"key":"10.1016\/j.abb.2018.11.021_bib302","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/eurjhf\/hfq031","article-title":"Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure","volume":"12","author":"Haehling","year":"2010","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.abb.2018.11.021_bib303","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.amjcard.2015.01.027","article-title":"Prognostic significance of adrenomedullin in patients with heart failure and with myocardial infarction","volume":"115","author":"Yuyun","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.abb.2018.11.021_bib304","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/ejhf.859","article-title":"Failure, Prognostic potential of midregional pro-adrenomedullin following decompensation for systolic heart failure: comparison with cardiac natriuretic peptides","volume":"19","author":"Morbach","year":"2017","journal-title":"Eur. J. Heart Fail."}],"container-title":["Archives of Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003986118306362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003986118306362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T06:07:58Z","timestamp":1757743678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003986118306362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":304,"alternative-id":["S0003986118306362"],"URL":"https:\/\/doi.org\/10.1016\/j.abb.2018.11.021","relation":{},"ISSN":["0003-9861"],"issn-type":[{"value":"0003-9861","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural and synthetic peptides in the cardiovascular diseases: An update on diagnostic and therapeutic potentials","name":"articletitle","label":"Article Title"},{"value":"Archives of Biochemistry and Biophysics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abb.2018.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}